Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Talazoparib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NICE greenlights Pfizer’s Talzenna for NHS use
    NICE greenlights Pfizer’s Talzenna for NHS use

    26 Jan 2026

    // PRESS RELEASE

    https://www.pharmaceutical-technology.com/news/uk-nice-recommends-pfizer-talzenna-metastatic-prostate-cancer/

    PRESS RELEASE
    26 Jan 2026
    Share Share
    Pfizer’s Talzenna Fails To Earn FDA Advisory Committee’s Support
    Pfizer’s Talzenna Fails To Earn FDA Advisory Committee’s Support

    23 May 2025

    // BIOSPACE

    https://www.biospace.com/fda/pfizers-talzenna-expansion-fails-to-earn-fda-advisory-committee-support

    BIOSPACE
    23 May 2025
    Share Share
    FDA Advisors Unanimously Reject Pfizer's Talzenna Expansion Bid
    FDA Advisors Unanimously Reject Pfizer's Talzenna Expansion Bid

    22 May 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/fda-advisors-unanimously-snub-pfizers-bid-expand-talzenna-broader-prostate-cancer-population

    FIERCE PHARMA
    22 May 2025
    Share Share
    Pfizer targets broad Talzenna label in prostate cancer
    Pfizer targets broad Talzenna label in prostate cancer

    11 Oct 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/pfizer-targets-broad-talzenna-approval-prostate-cancer-trial-meets-patient-survival-goal

    FIERCE PHARMA
    11 Oct 2024
    Share Share
    NICE reverses its call on Talzenna after Pfizer discount
    NICE reverses its call on Talzenna after Pfizer discount

    19 Jan 2024

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/pharma/after-pfizer-offers-discount-nice-gives-thumbs-breast-cancer-drug-talzenna

    Kevin Dunleavy FIERCE PHARMA
    19 Jan 2024
    Share Share
    EC Approves Pfizer’s TALZENNA®with XTANDI® for Prostate Cancer
    EC Approves Pfizer’s TALZENNA®with XTANDI® for Prostate Cancer

    08 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231221936013/en

    BUSINESSWIRE
    08 Jan 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.